Comments
Loading...
Spyre Therapeutics Analyst Ratings and Price Targets | NASDAQ:SYRE | Benzinga
Spyre Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Spyre Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Baird
Guggenheim
Wedbush
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Spyre Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | — | Leerink Partners | Faisal Khurshid30% | → $45 | Initiates | → Outperform | Get Alert |
| 12/11/2024 | Buy Now | — | Jones Trading | Debanjana Chatterjee27% | — | Initiates | → Hold | Get Alert |
| 11/13/2024 | Buy Now | — | Baird | Colleen Kusy32% | $50 → $65 | Maintains | Outperform | Get Alert |
| 10/25/2024 | Buy Now | — | Guggenheim | Yatin Suneja48% | $50 → $65 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | — | Wedbush | David Nierengarten57% | → $45 | Initiates | → Outperform | Get Alert |
| 07/16/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat42% | — | Initiates | → Outperform | Get Alert |
| 05/13/2024 | Buy Now | — | Wells Fargo | Yanan Zhu37% | $35 → $40 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | — | BTIG | Julian Harrison38% | $32 → $40 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | — | Baird | Colleen Kusy32% | → $50 | Initiates | → Outperform | Get Alert |
| 03/26/2024 | Buy Now | — | Stifel | Alex Thompson42% | $36 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | — | Wells Fargo | Yanan Zhu37% | $12 → $35 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/20/2023 | Buy Now | — | BTIG | Julian Harrison38% | → $32 | Initiates | → Buy | Get Alert |
| 12/18/2023 | Buy Now | — | Stifel | Alex Thompson42% | $23 → $27 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | — | Guggenheim | — | → $44 | Initiates | → Buy | Get Alert |
| 12/11/2023 | Buy Now | — | Jefferies | Akash Tewari41% | → $31 | Initiates | → Buy | Get Alert |
| 11/29/2023 | Buy Now | — | TD Cowen | Tyler Van Buren45% | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Spyre Therapeutics (SYRE) stock?
The latest price target for Spyre Therapeutics (NASDAQ:SYRE) was reported by Leerink Partners on April 8, 2025. The analyst firm set a price target for $45.00 expecting SYRE to rise to within 12 months (a possible 203.64% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spyre Therapeutics (SYRE)?
The latest analyst rating for Spyre Therapeutics (NASDAQ:SYRE) was provided by Leerink Partners, and Spyre Therapeutics initiated their outperform rating.
When was the last upgrade for Spyre Therapeutics (SYRE)?
The last upgrade for Spyre Therapeutics Inc happened on March 1, 2024 when Wells Fargo raised their price target to $35. Wells Fargo previously had an equal-weight for Spyre Therapeutics Inc.
When was the last downgrade for Spyre Therapeutics (SYRE)?
There is no last downgrade for Spyre Therapeutics.
When is the next analyst rating going to be posted or updated for Spyre Therapeutics (SYRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spyre Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spyre Therapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Spyre Therapeutics (SYRE) correct?
While ratings are subjective and will change, the latest Spyre Therapeutics (SYRE) rating was a initiated with a price target of $0.00 to $45.00. The current price Spyre Therapeutics (SYRE) is trading at is $14.82, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
